NCT07570966 2026-05-06Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNovartisPhase 1/2 Not yet recruiting217 enrolled